Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | CASP7 | P55210 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.31 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1035451 | 0.81 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL1037428 | 0.69 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL4663207 | 0.68 | AURKA (0.33) | AURKAAURKBINCENP | |
| SCHEMBL10370901 | 0.66 | AURKA (0.34) | AURKAAURKBINCENP | |
| SCHEMBL1038873 | 0.64 | — | — | |
| SCHEMBL1799123 | 0.63 | — | — | |
| SCHEMBL9769510 | 0.62 | FGFR1 (0.44) | KDM4EALDH1A1MAPT | |
| SCHEMBL28183364 | 0.62 | CYP3A4 (0.47) | KDM4EALDH1A1MAPT | |
| SCHEMBL7972 | 0.61 | MEN1 (0.31) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL2962726 | 0.60 | MCL1 (0.42) | KDM4EAURKAAURKBINCENP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018141749-A1 | THERAPEUTIC APPLICATIONS OF MALT1 INHIBITORS | MEDIVIR AB (SE) | 2018-08-09 | — | — | WO | disclosed |
| US-20120172361-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120095011-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-04-19 | — | — | US | disclosed |
| EP-2440052-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | Abraxis BioScience, LLC (US) | 2012-04-18 | — | — | EP | disclosed |
| WO-2010144359-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | ABRAXIS BIOSCIENCE, LLC (US) | 2010-12-16 | — | — | WO | disclosed |
| US-20090131463-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
| US-7521453-B2 | e.g. 5-Bromo-2-(3-methylisoxazol-5-ylmethylamino)-4-(5-cyclopropyl- 1H-pyrazol-3-ylamino)pyrimidine; anticarcinogenic, antitumor agents; breast, prostate, colon cancer | ASTRAZENECA AB (SE) | 2009-04-21 | — | — | US | disclosed |
| EP-1456182-B1 | PYRIMIDINE DERIVATIVES AS MODULATORS OF INSULINE-LIKE GROWTH FACTOR-1 RECEPTOR (IGF-I) | ASTRAZENECA AB (SE) | 2009-03-11 | — | — | EP | disclosed |
| US-20080167297-A1 | Pyrimidine Derivatives for Use as Anticancer Agents | ASTRAZENECA AB (SE) | 2008-07-10 | — | — | US | disclosed |
| US-20080161278-A1 | 2-Azetidinyl-4-(1H-Pyrazol-3-Ylamino) Pyrimidines as Inhibitors of Insulin-Like Growth Factor-1 Receptor Activity | ASTRAZENECA AB (SE) | 2008-07-03 | — | — | US | disclosed |
| US-20050054638-A1 | Pyrimidine derivatives as modulators of insulin-like growth factor-1 receptor (igf-i) | ASTRAZENECA AB | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167297-A1 | Pyrimidine Derivatives for Use as Anticancer Agents | IGF1R, TYMP, IGFBP1 | KDM4E 4044/4885MEN1 1371/4885ALDH1A1 458/4885 |
| US-20120172361-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CYP3A5, CYP11B2, ABCB1 | KDM4E 4209/4885MEN1 3723/4885ALDH1A1 213/4885 |
| US-20090131463-A1 | NOVEL COMPOUNDS | C1R, TBXA2R, F12 | KDM4E 1501/4885MEN1 789/4885ALDH1A1 1142/4885 |
| US-20080161278-A1 | 2-Azetidinyl-4-(1H-Pyrazol-3-Ylamino) Pyrimidines as Inhibitors of Insulin-Like Growth Factor-1 Receptor Activity | IGF1R, IGFBP1, IGFBP2 | KDM4E 3580/4885MEN1 592/4885ALDH1A1 740/4885 |
| US-20120095011-A1 | NOVEL COMPOUNDS | C1R, TBXA2R, F12 | KDM4E 1501/4885MEN1 789/4885ALDH1A1 1142/4885 |
| US-20050054638-A1 | Pyrimidine derivatives as modulators of insulin-like growth factor-1 receptor (igf-i) | IGF1R, IGFBP1, INSR | KDM4E 3536/4885MEN1 1458/4885ALDH1A1 1133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.